Related Experiment Videos
Non peptidic alphavbeta3 antagonists: recent developments
Barbara Cacciari1, Giampiero Spalluto
1Dipartimento di Scienze Farmaceutiche, Università degli Studi di Trieste, Piazzale Europa 1, I-34127 Trieste, Italy.
Current Medicinal Chemistry
|January 11, 2005
Summary
Researchers are developing non-peptidic integrin alphavbeta3 antagonists to treat diseases like osteoporosis and cancer. These inhibitors target cell adhesion and migration, offering new therapeutic avenues.
Area of Science:
- Biochemistry
- Cell Biology
- Pharmacology
Background:
- Integrin alphavbeta3, a cell adhesion molecule, plays a crucial role in cell-matrix adhesion, migration, and signaling.
- This receptor is expressed on mesenchymal cells and mediates processes like osteoblast adhesion, smooth muscle cell migration, and angiogenesis.
- Given its role in various pathophysiological conditions, significant research has focused on identifying alphavbeta3 receptor inhibitors.
Purpose of the Study:
- To summarize recent advancements in the development of non-peptidic antagonists targeting the integrin alphavbeta3 receptor.
Main Methods:
- Literature review of recent developments in non-peptidic alphavbeta3 antagonist research.
Main Results:
- Selective alphavbeta3 antagonists present therapeutic potential for osteoporosis, restenosis, and neovascularization-related diseases.
- These include rheumatoid arthritis, tumor-induced angiogenesis, and metastasis.
Conclusions:
- Non-peptidic alphavbeta3 antagonists are a promising area of therapeutic development.
- Targeting alphavbeta3 offers new strategies for managing various human pathologies.